Friday, March 23, 2012 3:49:47 PM
thanks. just FYI, current market cap has us valued at around 14 million, and the company pulled in 27 million in revenues for the first three quarters of 2011.
the company's value suffered the way it has because of a toxic investment in a fledgling music service called "kazaa", which not only provided little in the way of revenues, but managed to suck profits from ATRN's bottom line, as well as dig heavily into cash reserves.
as of Q4 in 2011, ATRN has (wisely, and finally) dumped the kazaa service...thus losing this toxic drain on their income statement.
a 10K for all of 2011, including Q4 for 2011, is due by march 31st. there is a possibility the company will file for an extension into the first week of april (they did this last year).
many are hoping that the 10K will show revenues around 35 million.
I highly encourage you to take a few moments to check out the company's fundamentals.
the company's value suffered the way it has because of a toxic investment in a fledgling music service called "kazaa", which not only provided little in the way of revenues, but managed to suck profits from ATRN's bottom line, as well as dig heavily into cash reserves.
as of Q4 in 2011, ATRN has (wisely, and finally) dumped the kazaa service...thus losing this toxic drain on their income statement.
a 10K for all of 2011, including Q4 for 2011, is due by march 31st. there is a possibility the company will file for an extension into the first week of april (they did this last year).
many are hoping that the 10K will show revenues around 35 million.
I highly encourage you to take a few moments to check out the company's fundamentals.
Recent PTIX News
- Protagenic Therapeutics Completes Phytanix Separation, Strengthens Balance Sheet and Repositions the Company Around PT00114 • ACCESS Newswire • 03/17/2026 12:00:00 PM
- Protagenic Therapeutics Upgrades from OTC Pink to OTCQB Venture Market • ACCESS Newswire • 03/10/2026 12:00:00 PM
- Results from Phase 1 Multiple-Dose Study of PT00114 • ACCESS Newswire • 12/09/2025 01:46:00 PM
- Protagenic Therapeutics Announces Receipt of Nasdaq Non-Compliance Notice • ACCESS Newswire • 11/27/2025 08:45:00 AM
- Protagenic Therapeutics Announces Completion of Enrollment and Dosing in Phase 1 MAD Study • ACCESS Newswire • 11/13/2025 01:22:00 PM
- Protagenic Therapeutics Announces Grant of new patent in Japan for its Modified Stilbenoid Program Drug Candidates • GlobeNewswire Inc. • 07/30/2025 12:30:00 PM
- Nasdaq Top 5 Premarket Losers • IH Market News • 05/20/2025 12:47:37 PM
- Protagenic Therapeutics Soars 190% on Merger to Launch Neuroactive Biopharma Firm • IH Market News • 05/19/2025 02:28:09 PM
- Nasdaq Top 5 Premarket Gainers • IH Market News • 05/19/2025 01:07:08 PM
